查看文章

Respiratory syncytial virus (RSV) infections may be fatal in immunocompromised patients. Aerosolized ribavirin is used for treatment, but it is very costly, teratogenic, and inconvenient. We aimed to assess the outcome of oral ribavirin treatment, with or without intravenous immunoglobulin (IVIG), for RSV infections in moderately to severely immunocompromised patients.

Medical records of RSV polymerase chain reaction (PCR)‐positive patients during 2011–2013 were reviewed retrospectively. Eligible patients were moderately to severely immunocompromised and received oral ribavirin (600–800 mg twice daily) with or without IVIG (500 mg/kg q 48 h) as per protocol.

Of 96 adults with PCR‐proven RSV infection, 34 were moderately to severely immunocompromised and received oral ribavirin treatment. The mean age was 56.2 years (range: 18–90); 21 were male. Underlying …